Concentra Group Holdings Parent, Inc. filings document the public reporting of a NYSE-listed occupational health services company with common stock registered under the symbol CON. Recent Form 8-K disclosures cover results of operations and financial condition, Regulation FD presentations, dividend declarations, preliminary operating metrics, and material executive and compensation matters.
The company's proxy and annual-meeting filings disclose board elections, advisory executive compensation votes, auditor ratification, stockholder voting results, and governance procedures. Other filings describe executive equity awards under the 2024 Equity Incentive Plan, leadership succession disclosures, and the company's Delaware corporate and capital-stock structure.
Concentra Group Holdings Parent, Inc. director Robert A. Ortenzio reported an indirect open-market sale of 130,000 shares of common stock at $25.00 per share. The sale was made by The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio, which held 893,455 shares afterward. Additional indirect family trusts and direct holdings include 5,533,794 shares reported as directly owned.
CON filed a Form 144 notice reporting an intended sale of 130,000 shares of Common Stock with an aggregate offering price of $3,250,000.00. The filing lists shares outstanding of 127,961,780 as of 05/08/2026 and shows prior private purchase lots on 04/29/2005, 06/02/2005, and 11/08/2005.
Concentra Group Holdings Parent, Inc. reported strong first-quarter 2026 results with revenue of $569.6 million, up 13.7% from a year earlier, driven by higher visit volumes and revenue per visit. Net income rose 28.7% to $52.3 million, and earnings per share increased to $0.39 from $0.30. Adjusted EBITDA reached $120.7 million, a 17.6% increase, with margin improving to 21.2%.
The company generated $9.9 million of Free Cash Flow, repurchased about 0.7 million shares for $15.0 million, and ended the quarter with $61.7 million of cash and a net leverage ratio of roughly 3.4x. The board declared a quarterly cash dividend of $0.0625 per share payable in June 2026. Concentra raised its full-year 2026 guidance, now expecting revenue of $2.275–$2.375 billion, Adjusted EBITDA of $460–$480 million, Free Cash Flow of $215–$235 million, capital expenditures of $70–$80 million, and a year-end net leverage ratio below 3.0x.
Concentra Group Holdings Parent, Inc. reported the results of its annual stockholder meeting. Three Class II directors—Vipin Gopal, William K. Newton, and Marc R. Watkins, MD—were elected to serve until the 2029 annual meeting, with each nominee receiving strong support based on votes cast.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 114,180,227 votes in favor and 5,143,479 against. In addition, stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 121,568,869 votes for and 360,888 against.
Concentra Group Holdings Parent Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 6,837,148 shares of Common Stock, representing 5.32% of the class as of 03/31/2026. Vanguard reports 98,223 shares of sole voting power and sole dispositive power over 6,837,148 shares. The filing notes these holdings include shares held for Vanguard funds and managed accounts and is signed by a Vanguard representative on 04/29/2026.
Concentra Group Holdings Parent, Inc. announced that Executive Vice President and Chief Medical Officer Dr. John Anderson will retire effective December 31, 2026, after 33 years with the company. He plans to continue advising Concentra under a consulting arrangement to support a smooth transition while the company conducts a formal search for his successor.
Dr. Anderson has served as Chief Medical Officer since 2014 and is widely involved in occupational and environmental medicine organizations. Concentra describes itself as the largest U.S. provider of occupational health services by number of locations, with approximately 13,000 colleagues supporting care for about 53,000 patients each business day across 47 states and the District of Columbia as of December 31, 2025.
Concentra Group Holdings Parent Inc — Amendment No. 2 to a Schedule 13G/A reports that The Vanguard Group holds 0 shares (0%) of Common Stock following an internal realignment effective January 12, 2026. The filing states, in accordance with SEC Release No. 34-39538 (January 12, 1998), certain Vanguard subsidiaries will report beneficial ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Concentra Group Holdings Parent, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on April 30, 2026 at 11:00 a.m. CDT. Stockholders of record as of March 5, 2026, when 128,507,289 common shares were outstanding, may vote online.
Investors are asked to elect three Class II directors for three-year terms, approve on a non-binding basis the compensation of named executive officers, and ratify PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. The Board recommends voting FOR all three proposals.
The proxy describes Concentra’s governance structure, including a majority-independent seven-member Board, an independent Lead Director, and four fully independent committees. It also details executive pay philosophy emphasizing performance-based bonuses and equity, 2025 restricted stock grants (e.g., 225,000 shares to CEO William Newton), stock ownership guidelines, clawback and anti-hedging policies, and cybersecurity oversight under a NIST-based framework.